Faïza Khemissa

667 total citations
24 papers, 257 citations indexed

About

Faïza Khemissa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Faïza Khemissa has authored 24 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in Faïza Khemissa's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Faïza Khemissa is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Faïza Khemissa collaborates with scholars based in France, Canada and Switzerland. Faïza Khemissa's co-authors include Thomas Aparicio, Olivier Bouché, Francesco Savinelli, Bruno Raynard, Nicolas Flori, Sandrine Oziel-Taïeb, Xavier Hébuterne, Jean Lacau Saint Guily, Jean–Marc Phelip and François Ghiringhelli and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and Annals of Oncology.

In The Last Decade

Faïza Khemissa

22 papers receiving 251 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Faïza Khemissa France	8	149	87	60	47	46	24	257
Mohamed Ramdani France	6	123 0.8×	101 1.2×	78 1.3×	84 1.8×	49 1.1×	10	299
Fatih Saygılı Türkiye	9	104 0.7×	105 1.2×	53 0.9×	44 0.9×	123 2.7×	18	286
Soichi Iritani Japan	8	63 0.4×	197 2.3×	36 0.6×	72 1.5×	74 1.6×	15	324
Elia Gigante France	10	87 0.6×	109 1.3×	33 0.6×	39 0.8×	126 2.7×	23	356
Keitaro Edahiro Japan	7	124 0.8×	196 2.3×	72 1.2×	111 2.4×	126 2.7×	16	312
Paola Begini Italy	9	72 0.5×	135 1.6×	22 0.4×	53 1.1×	27 0.6×	22	294
Shunji Koya Japan	10	47 0.3×	154 1.8×	23 0.4×	43 0.9×	21 0.5×	19	243
Norimitsu Yabusaki Japan	6	224 1.5×	134 1.5×	58 1.0×	68 1.4×	108 2.3×	10	319
C. Locher France	6	160 1.1×	106 1.2×	182 3.0×	57 1.2×	119 2.6×	8	363
Shotaro Korehisa Japan	8	145 1.0×	195 2.2×	77 1.3×	111 2.4×	126 2.7×	15	341

Countries citing papers authored by Faïza Khemissa

Since Specialization

Citations

This map shows the geographic impact of Faïza Khemissa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faïza Khemissa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faïza Khemissa more than expected).

Fields of papers citing papers by Faïza Khemissa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Faïza Khemissa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faïza Khemissa. The network helps show where Faïza Khemissa may publish in the future.

Co-authorship network of co-authors of Faïza Khemissa

This figure shows the co-authorship network connecting the top 25 collaborators of Faïza Khemissa. A scholar is included among the top collaborators of Faïza Khemissa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Faïza Khemissa. Faïza Khemissa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merle, P., Julien Edeline, Karine Le Malicot, et al.. (2025). 1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC. Annals of Oncology. 36. S822–S822.

Tougeron, David, Jean‐François Emile, Emilie Barbier, et al.. (2024). LBA1 Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial. Annals of Oncology. 35. S212–S212. 1 indexed citations

Ducreux, Michel, Aurélie Parzy, Méher Ben Abdelghani, et al.. (2021). 508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 32. S580–S581. 1 indexed citations

Samalin, Emmanuelle, Anthony Turpin, Faïza Khemissa, et al.. (2019). Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). Annals of Oncology. 30. iv21–iv21. 2 indexed citations

Lopez‐Crapez, Evelyne, Antoine Adenis, Simon Thézenas, et al.. (2018). FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.. Journal of Clinical Oncology. 36(15_suppl). 3548–3548. 5 indexed citations

Ychou, Marc, Michel Rivoire, Simon Thézenas, et al.. (2018). Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.. Journal of Clinical Oncology. 36(15_suppl). 3535–3535. 6 indexed citations

Khemissa, Faïza, J.-P. Bronowicki, Jean–Marc Perarnau, et al.. (2018). Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients. Journal of Hepatology. 68. S195–S195. 7 indexed citations

Aparicio, Thomas, François Ghiringhelli, Valérie Boige, et al.. (2018). Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). Journal of Clinical Oncology. 36(7). 674–681. 59 indexed citations

Zaanan, Aziz, Emmanuelle Samalin, Christophe Louvet, et al.. (2017). PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma. Annals of Oncology. 28. v265–v265. 4 indexed citations

10.

Gyan, Emmanuel, Bruno Raynard, Jean Lacau Saint Guily, et al.. (2017). Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians—Results of the NutriCancer2012 Study. Journal of Parenteral and Enteral Nutrition. 42(1). 255–260. 86 indexed citations

11.

Samalin, Emmanuelle, Hélène Senellart, Simon Thézenas, et al.. (2017). Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v179–v179. 1 indexed citations

12.

Ychou, Marc, Michel Rivoire, Simon Thézenas, et al.. (2016). FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.. Journal of Clinical Oncology. 34(15_suppl). 3512–3512. 14 indexed citations

13.

Aparicio, Thomas, Jaafar Bennouna, Karine Le Malicot, et al.. (2016). Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). 3531–3531. 7 indexed citations

14.

Khemissa, Faïza, Laurent Mineur, Eric Assénat, et al.. (2015). A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm. Digestive and Liver Disease. 48(3). 327–332. 10 indexed citations

15.

Aparicio, Thomas, Olivier Bouché, Éric François, et al.. (2015). PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.. Journal of Clinical Oncology. 33(15_suppl). 3541–3541. 6 indexed citations

16.

Manfrédi, Sylvain, Olivier Bouché, Philippe Rougier, et al.. (2015). High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study. Molecular Cancer Therapeutics. 14(12). 2782–2788. 7 indexed citations

17.

Raynard, Bruno, Sébastien Gouy, Nicolas Flori, et al.. (2013). P181 Patients, proches et médecins n’ont pas la même vision de la dénutrition en cancérologie. Résultats de l’étude NUTRICANCER 2012. Nutrition Clinique et Métabolisme. 27. S145–S146. 1 indexed citations

18.

Mitry, Emmanuel, Jean–Marc Phelip, Franck Bonnetain, et al.. (2008). Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001–02 trial). Results of a planned interim analysis. Critical Reviews in Oncology/Hematology. 68. S23–S23. 15 indexed citations

19.

Sénesse, Pierre, Faïza Khemissa, C. Lemanski, et al.. (2001). [Contribution of endorectal ultrasonography in preoperative evaluation for very low rectal cancer].. PubMed. 25(1). 24–8. 6 indexed citations

20.

Jp, Daurès, et al.. (1999). [Measurement of the quality of life in chronic hepatitis C: validation of a general index and specific index. First French results].. PubMed. 23(12). 1296–309. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact